Cellectis S.A.
Cellectis S.A. is a France-based cell therapy company running 2 late-stage cancer trials of CLLS52 and UCART22 in acute lymphoblastic leukaemia and hodgkin lymphoma.
Overview
Cellectis S.A., based in Paris, France, is a cell therapy company listed as NASDAQ: CLLS / Euronext Growth: ALCLS. Cellectis is a biotechnology company that develops off-the-shelf (allogeneic) CAR T-cell therapies for cancer using its TALEN gene-editing and PulseAgile electroporation technology platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing CLLS52 and UCART22 in acute lymphoblastic leukaemia and hodgkin lymphoma. The largest, NCT05607420 (Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma), plans to enrol 80 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Scorecard
All companies- phase 1/2 +1
- targets +2
- modalities +2
Similar pages
not linked directly; found by shared links- CompanyShenzhen TargetRx
Shares Hodgkin lymphoma, Acute lymphoblastic leukaemia and the tag ctgov-sponsor.
- CompanyHaihe Biopharma
Shares Hodgkin lymphoma and the tag ctgov-sponsor.
- CompanyKartos Therapeutics
Shares Hodgkin lymphoma and the tag ctgov-sponsor.
- CompanyRyvu Therapeutics
Shares Hodgkin lymphoma and the tag ctgov-sponsor.
- CompanyEvopoint Biosciences
Shares Hodgkin lymphoma and the tag ctgov-sponsor.
- IdeaDefault fertility preservation referral for every patient under 40 before treatment
- IdeaCash for transport and food to stop families abandoning curative treatment
- IdeaGuaranteed-quality childhood cancer medicines free of charge in 50 countries